BKD
Brookdale Senior Living Inc.
BKD has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over BKD overall, supported by stronger fundamentals and stronger modeled upside.
BKD Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Stable | |
| Under pressure | |
| Weak |
BKD's profitability is currently stable, but its revenue, cash flow and balance sheet are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
BKD PE Valuation
BKD has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 460x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
BKD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Stable | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect BKD to return to profit, with revenue holding steady. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over BKD on the outlook, with more favorable revenue expectations.
BKD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.02 | — |
| Q3 2026 | -$0.17 | +$1.14 |
| Q2 2026 | -$0.59 | +$0.46 |
| Q1 2026 | -$0.87 | +$0.17 |
| Q4 2025 | -$1.12 | -$0.23 |
| Q3 2025 | -$1.31 | -$0.39 |
| Q2 2025 | -$1.05 | -$0.13 |
| Q1 2025 | -$1.04 | -$0.27 |
| Q4 2024 | -$0.89 | -$0.05 |
BKD is still losing money, but far less than before: $0.17 per share over the past year, against $2.15 at its worst in early 2021.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over BKD on earnings quality, reporting a profit while its opponent remains loss making.
BKD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $712.1M | -12% |
| Q2 2026 | $718.6M | -12% |
| Q1 2026 | $764.9M | -6% |
| Q4 2025 | $754.1M | -3.4% |
| Q3 2025 | $813.2M | +3.7% |
| Q2 2025 | $812.9M | +4.6% |
| Q1 2025 | $813.9M | +4% |
| Q4 2024 | $780.9M | +3.5% |
BKD's revenue has slid since its 2020 peak: $712M last quarter, down 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +12 points |
| Q2 2026 | 12% | +10 points |
| Q1 2026 | 6.8% | +3.1 points |
| Q4 2025 | 3% | +3.3 points |
| Q3 2025 | -6.6% | -7.9 points |
| Q2 2025 | 1.8% | -0.6 points |
| Q1 2025 | 3.6% | +1.2 points |
| Q4 2024 | -0.3% | +2.9 points |
BKD has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over BKD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
BKD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $25.7M | -26% |
| Q2 2026 | $43.5M | +49% |
| Q1 2026 | -$25.6M | -$7.2M |
| Q4 2025 | -$29.1M | -$24M |
| Q3 2025 | $34.9M | +204% |
| Q2 2025 | $29.1M | +610% |
| Q1 2025 | -$18.4M | +$27.1M |
| Q4 2024 | -$5.1M | +$24.1M |
BKD has burned cash in most quarters: $15M over the past year, down 64% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over BKD on cash flow, with more consistent year-over-year improvement.
BKD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.9% | -4.7M shares |
| 1 year | +0.7% | +1.7M shares |
| 3 years | +6.1% | +13.7M shares |
| 5 years | +22% | +42.9M shares |
| Available history | +29% | +53.2M shares |
BKD has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | $18.1M |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
BKD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 8.0x | High |
| Q2 2026 | 9.1x | High |
| Q1 2026 | 10.6x | High |
| Q4 2025 | 10.7x | High |
| Q3 2025 | 10.9x | High |
| Q2 2025 | 9.5x | High |
| Q1 2025 | 9.6x | High |
| Q4 2024 | 9.2x | High |
BKD's net debt is about 8.0 years of its operating earnings (EBITDA), down from 11 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over BKD on leverage, with a lower net debt burden relative to earnings.
BKD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.0 | Oversold |
| Stochastic | 6.9 | Oversold |
BKD's weekly RSI is 29 (oversold) and its Stochastic is 7 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
BKD PE vs Healthcare Sector
| Metric | BKD | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
BKD has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
BKD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.1 | 11% below |
| 20 week MA | $12.1 | 26% below |
| 50 week MA | $12.8 | 30% below |
| 100 week MA | $9.91 | 9.6% below |
| 200 week MA | $7.54 | 19% above |
BKD has fallen below most of its moving averages, though it's still 19% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over BKD on trend strength, trading above more of its moving averages.
BKD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $7.01 | $4.21 | -40% |
| 2021 | $4.21 | $5.17 | +23% |
| 2022 | $5.17 | $2.71 | -48% |
| 2023 | $2.71 | $5.82 | +115% |
| 2024 | $5.82 | $5.07 | -13% |
| 2025 | $5.07 | $10.9 | +115% |
| 2026 YTD | $10.9 | $8.96 | -18% |
BKD's yearly returns have swung widely, from +115% in 2025 to −48% in 2022. It's down 18% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over BKD on returns for 2026, with the stronger performance.